about
Efficacy and safety of deep transcranial magnetic stimulation for major depression: a prospective multicenter randomized controlled trialUpdate on Neuromodulation for Treatment-Resistant DepressionCitalopram plus low-dose pipamperone versus citalopram plus placebo in patients with major depressive disorder: an 8-week, double-blind, randomized study on magnitude and timing of clinical responseDiminished appetitive startle modulation following targeted inhibition of prefrontal cortexRepetitive transcranial magnetic stimulation activates specific regions in rat brain.Psycho-informatics: Big Data shaping modern psychometrics.Deep brain stimulation to the medial forebrain bundle for depression- long-term outcomes and a novel data analysis strategy.Autonomy in Depressive Patients Undergoing DBS-Treatment: Informed Consent, Freedom of Will and DBS' Potential to Restore ItConsensus on guidelines for stereotactic neurosurgery for psychiatric disorders.Rapid effects of deep brain stimulation for treatment-resistant major depression.Deep brain stimulation of the human reward system for major depression--rationale, outcomes and outlook.Scientific and ethical issues related to deep brain stimulation for disorders of mood, behavior, and thought.Deep brain stimulation to reward circuitry alleviates anhedonia in refractory major depression.Nucleus accumbens deep brain stimulation decreases ratings of depression and anxiety in treatment-resistant depression.Mechanisms and state of the art of vagus nerve stimulation.Efficacy of repetitive transcranial magnetic stimulation (rTMS) in the treatment of affective disorders.Repetitive transcranial magnetic stimulation for the treatment of depression. Systematic review and meta-analysis.Long-term effects of nucleus accumbens deep brain stimulation in treatment-resistant depression: evidence for sustained efficacy.Reduced 5-HT(2A) receptor signaling following selective bilateral amygdala damage.Noradrenergic enhancement of amygdala responses to fearNuclei accumbens phase synchrony predicts decision-making reversals following negative feedbackStimulating personality: ethical criteria for deep brain stimulation in psychiatric patients and for enhancement purposes.WFSBP Guidelines on Brain Stimulation Treatments in Psychiatry.Controversy: Repetitive transcranial magnetic stimulation or transcranial direct current stimulation shows efficacy in treating psychiatric diseases (depression, mania, schizophrenia, obsessive-complusive disorder, panic, posttraumatic stress disordCross-species affective functions of the medial forebrain bundle-implications for the treatment of affective pain and depression in humans.Aripiprazole in patients with bipolar mania and beyond: an update of practical guidance.The hidden third: improving outcome in treatment-resistant depression.Brain stimulation therapies for neuropsychiatric disease.Diffusion tensor imaging and neuromodulation: DTI as key technology for deep brain stimulation.Neuromodulation for treatment resistant depression: state of the art and recommendations for clinical and scientific conduct.Deep brain stimulation for major depression.Deep brain stimulation for bipolar disorder-review and outlook.Misuse of the FDA's humanitarian device exemption in deep brain stimulation for obsessive-compulsive disorder.Electrodes in the brain--ethical criteria for research and treatment with deep brain stimulation for neuropsychiatric disorders.Safety and feasibility of magnetic seizure therapy (MST) in major depression: randomized within-subject comparison with electroconvulsive therapy.Mood effects of repetitive transcranial magnetic stimulation of left prefrontal cortex in healthy volunteers.Modulating affect, cognition, and behavior - prospects of deep brain stimulation for treatment-resistant psychiatric disorders.Chronic vagus nerve stimulation for treatment-resistant depression increases regional cerebral blood flow in the dorsolateral prefrontal cortex.Magnetic seizure therapy in treatment-resistant depression: clinical, neuropsychological and metabolic effects.The N-methyl-D-aspartate receptor co-agonist D-cycloserine facilitates declarative learning and hippocampal activity in humans.
P50
Q26285020-578E12DC-AA4C-48C7-AE1E-7C361B4A080FQ26766211-AD1F19C5-016B-4680-B6B7-ED6973E53AB0Q28306033-D3CC41C0-B63F-48C1-B04B-81300432ACF7Q30416674-6684DDF6-4107-4BBE-AE72-CFBB5FE30890Q30530650-825700D2-330F-4175-9A6A-24AF6613F409Q30757581-FAE0FAFE-709C-401A-8D1D-3C0009EAFA9CQ31170750-251881AE-0715-47DD-BD6C-DDF6E5E8B893Q33774713-C9136B43-C4D7-4819-8932-C3591E22CF0DQ34092378-B5015DE9-7ABC-4E78-AB89-BAE1A0C35457Q34337593-C8FE9C71-F966-4662-A871-59F4D8B60896Q34403430-9A1D9F8E-DCBA-4FA7-BD62-462E276DBAA5Q34611603-D0FDE97D-B923-447D-BC19-C9F96E570875Q34618440-E2650C50-7064-4A5F-AA9F-2F2FC07FFAC2Q35012957-1B7C50AA-07EE-4246-B7EC-AA984789131AQ35018390-9E410B8E-8387-41F5-B2D0-F17C744D4B90Q35067542-4E6F93EE-13F9-484A-B14B-11119AC23870Q35141247-B3DE7F06-A397-4999-83D6-7C95F3732823Q36100400-4EB613F2-CFCF-4144-90FD-F9DDB248640BQ37131261-13E5A0E4-ED2A-4E2F-9ADC-364FCCDEB2FEQ37202089-245B4602-9767-46B9-A04F-523277326212Q37301537-4230C373-4D06-47E8-87B2-5A1E3F8AC2EBQ37346295-86D11F09-63AB-47BB-916D-C8E127C3BBF5Q37690334-C291DAFB-6D28-4E6A-8B34-61FDF9C1AC46Q37773018-FF2655B7-D050-4D37-B0F6-63D920D97B5DQ37823931-CDE145A5-1E85-4C93-BDDF-DF2FD3B5E300Q37947705-7110ED64-C4D0-4F43-A0E2-1A314C79CDC7Q37974998-1855287E-1459-4F8E-A82F-856070F08C3FQ38011439-EA0030D3-DDD6-4090-9E5D-61BFBCD849FEQ38064597-CEC1DFB3-8646-46E2-8E4C-8AE263B075A7Q38145016-CDDCFCBB-ED9D-4ACB-8436-560730A88303Q38151323-61DB077E-D985-47DA-B257-CDE2E3F2E12EQ38728298-E9739CBE-CD69-4BFC-8949-CC02E26B3DD2Q39225600-C2EC15C9-A517-4771-BA71-D2FD8E66B185Q39791144-9A3DA73A-A6E2-42BE-AFE9-7AC07A0F5473Q40574493-2CD01FDB-FA5F-4D7B-A705-A6CA0A668A07Q40757883-11B1243C-9E54-48D4-8A93-2F219E84862CQ42218223-882B3ACE-F675-4324-944E-81D4148FDEA7Q42689706-8E1C03EE-B61C-425B-BC0C-43F4080D4D88Q42694571-38809E1C-E9DC-427F-A80A-0A3F4F55070BQ43123374-1FE03512-2B1D-4A09-B397-4A6D3F9D7857
P50
description
hulumtues
@sq
researcher
@en
ricercatore
@it
wetenschapper
@nl
հետազոտող
@hy
name
Thomas E Schlaepfer
@nl
Thomas E Schlaepfer
@sl
Thomas E. Schlaepfer
@en
Thomas E. Schlaepfer
@es
type
label
Thomas E Schlaepfer
@nl
Thomas E Schlaepfer
@sl
Thomas E. Schlaepfer
@en
Thomas E. Schlaepfer
@es
altLabel
Schlaepfer
@en
Schlapfer Schläpfer
@en
prefLabel
Thomas E Schlaepfer
@nl
Thomas E Schlaepfer
@sl
Thomas E. Schlaepfer
@en
Thomas E. Schlaepfer
@es
P106
P1153
7004061357
P21
P214
2973148997636759870007
P31
P496
0000-0003-0612-9692
P734
P735
P7859
viaf-2973148997636759870007